Transgene Biotek Ltd
₹ 3.08
2.67%
05 Dec
- close price
About
Incorporated in 1990, Transgene Biotek Limited is in the business of Research & Development of Pharmaceutical products. The registered office of the company is in Telangana.[1]
Key Points
- Market Cap ₹ 23.3 Cr.
- Current Price ₹ 3.08
- High / Low ₹ 8.00 / 2.90
- Stock P/E
- Book Value ₹ 1.22
- Dividend Yield 0.00 %
- ROCE -1.75 %
- ROE -6.56 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 2.53 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 23.6%
- Company has a low return on equity of -20.5% over last 3 years.
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Loading peers table ...
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.98 | 0.30 | 0.18 | 0.28 | 0.12 | 0.07 | 0.00 | 0.17 | 0.09 | 0.06 | 0.23 | 0.26 | 0.26 | |
| 2.81 | 1.90 | 1.32 | 2.84 | 2.22 | 0.75 | 0.87 | 0.70 | 0.55 | 0.68 | 0.83 | 1.38 | 1.10 | |
| Operating Profit | -1.83 | -1.60 | -1.14 | -2.56 | -2.10 | -0.68 | -0.87 | -0.53 | -0.46 | -0.62 | -0.60 | -1.12 | -0.84 |
| OPM % | -186.73% | -533.33% | -633.33% | -914.29% | -1,750.00% | -971.43% | -311.76% | -511.11% | -1,033.33% | -260.87% | -430.77% | -323.08% | |
| -114.37 | 0.01 | 0.17 | 0.66 | 7.37 | 2.04 | 0.18 | 0.27 | 0.21 | 0.18 | 0.18 | 0.78 | 0.08 | |
| Interest | 0.00 | 0.36 | 0.07 | 0.43 | 1.03 | 0.26 | 0.38 | 0.27 | 0.23 | 0.62 | 0.14 | 0.24 | 0.72 |
| Depreciation | 17.22 | 17.18 | 20.50 | 17.53 | 9.89 | 9.89 | 9.90 | 9.91 | 9.92 | 4.95 | 0.09 | 0.09 | 0.14 |
| Profit before tax | -133.42 | -19.13 | -21.54 | -19.86 | -5.65 | -8.79 | -10.97 | -10.44 | -10.40 | -6.01 | -0.65 | -0.67 | -1.62 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 13.98% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| -133.41 | -19.14 | -21.54 | -19.86 | -6.44 | -8.79 | -10.96 | -10.43 | -10.40 | -6.01 | -0.66 | -0.68 | -1.62 | |
| EPS in Rs | -17.61 | -2.53 | -2.84 | -2.62 | -0.85 | -1.16 | -1.45 | -1.38 | -1.37 | -0.79 | -0.09 | -0.09 | -0.21 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | % |
| 3 Years: | 42% |
| TTM: | 24% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 14% |
| 3 Years: | 25% |
| TTM: | -523% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | -9% |
| 3 Years: | 3% |
| 1 Year: | -60% |
| Return on Equity | |
|---|---|
| 10 Years: | -19% |
| 5 Years: | -34% |
| 3 Years: | -21% |
| Last Year: | -7% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 | 75.77 |
| Reserves | 130.20 | 115.62 | 98.67 | -16.90 | -23.34 | -32.13 | -43.10 | -53.53 | -58.39 | -64.40 | -65.06 | -65.74 | -66.56 |
| 13.06 | 14.43 | 15.28 | 16.01 | 9.84 | 9.14 | 10.33 | 11.33 | 12.01 | 13.11 | 14.00 | 14.52 | 16.50 | |
| 139.32 | 137.95 | 123.27 | 123.18 | 124.28 | 123.77 | 123.75 | 123.31 | 117.71 | 117.87 | 117.62 | 119.54 | 118.04 | |
| Total Liabilities | 358.35 | 343.77 | 312.99 | 198.06 | 186.55 | 176.55 | 166.75 | 156.88 | 147.10 | 142.35 | 142.33 | 144.09 | 143.75 |
| 180.58 | 163.40 | 140.95 | 61.16 | 50.97 | 41.10 | 31.20 | 21.32 | 11.40 | 6.45 | 6.36 | 9.83 | 9.73 | |
| CWIP | 0.29 | 0.29 | 0.29 | 2.04 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 1.87 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 |
| 177.48 | 180.08 | 171.75 | 134.86 | 133.71 | 133.58 | 133.68 | 133.69 | 133.73 | 133.93 | 134.00 | 134.16 | 133.92 | |
| Total Assets | 358.35 | 343.77 | 312.99 | 198.06 | 186.55 | 176.55 | 166.75 | 156.88 | 147.10 | 142.35 | 142.33 | 144.09 | 143.75 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.11 | 3.52 | 6.47 | 0.02 | -0.63 | -1.74 | 0.14 | 0.01 | 0.10 | 0.00 | 0.00 | 1.20 | |
| 1.45 | -4.57 | -6.47 | 0.00 | 3.05 | 1.74 | 0.00 | -0.03 | -0.10 | -0.01 | 0.00 | -1.70 | |
| 0.60 | 1.03 | 0.00 | 0.00 | -2.37 | 0.00 | -0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.78 | |
| Net Cash Flow | -0.05 | -0.02 | 0.00 | 0.02 | 0.05 | 0.00 | -0.06 | -0.01 | 0.00 | -0.01 | 0.00 | 0.28 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 6,797.19 | 19,953.33 | 3,325.56 | 13.04 | 30.42 | 52.14 | 21.47 | 40.56 | 60.83 | 15.87 | 14.04 | |
| Inventory Days | 106.46 | 365.00 | 365.00 | 1,460.00 | 121.67 | 156.43 | ||||||
| Days Payable | 25,975.83 | 5,018.75 | 3,528.33 | 13,870.00 | 1,460.00 | 1,199.29 | ||||||
| Cash Conversion Cycle | -19,072.18 | 19,953.33 | 3,325.56 | 13.04 | -4,623.33 | -3,111.19 | -1,316.86 | 40.56 | -982.02 | 15.87 | 14.04 | |
| Working Capital Days | -2,007.50 | -8,528.83 | -16,019.44 | -14,339.29 | -39,967.50 | -62,519.29 | -29,092.65 | -34,593.89 | -57,365.83 | -15,933.04 | -16,509.23 | |
| ROCE % | -6.48% | -8.83% | -10.86% | -14.69% | -10.97% | -17.91% | -22.11% | -26.56% | -32.31% | -20.01% | -2.07% | -1.75% |
Documents
Announcements
- Intimation Of Book Closure And Cut -Off Date For The 35Th Annual General Meeting Of Transgene Biotek Limited With Reference To The Subject Cited, This Is To Inform That The Register Of Members And The Share Transfer Books Of The Company Will Remain Closed From Tuesday The 24Th December 2025 To Tuesday The 30Th December, 2025 (Both Days Inclusive) For The Purpose Of 35Th Annual General Meeting Which Is Scheduled To Be Held On Tuesday The 30Th December 2025 At IST Through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM') At 11.00 A.M. (IST). 7h
- Reg. 34 (1) Annual Report. 12h
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
20 Nov - Newspaper Advertisement of financial results under regulation 47 of SEBI (LODR) Regulations, 2015.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On November 14, 2025.
14 Nov - Approved Q2 results (H1 loss ₹82.21L); AGM Dec30; e-voting Dec27-29; reappointed CMD and three IDs; SAT/NCLT hearings.
- Un-Audited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30, 2025. (Copy Enclosed) 14 Nov
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Expertise:[1]
Company is in production and oral formulation of different proteins using TrabiORAL technology
a) Oncology[2]
b) Auto Immunity[3]
c) Drug Delivery[4]
d) Biogenerics[5]